跳到正文
← 返回论文列表与筛选
阅读说明

本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。

DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。

本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。

引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。

关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。

分类依据与纠错

AI 根据所提供的论文材料归类:摘要明确围绕直接效应、间接效应及生存结局的因果中介分析展开。

反馈分类问题

正在核对关联版本…

代码、数据与补充材料

正在核对对应版本的资源…

关注这篇论文的作者
Alex Ocampo
Enrico Giudice
Dieter A. Häring
Baldur Magnusson
Theis Lange
Zachary R. McCaw

用伪值简化事件发生时间结局的因果中介分析

研究问题
生存结局的风险比难以作直观的直接与间接效应分解,能否改用其他效应尺度,简化因果中介效应的估计和推断?
方法与思路
作者用考虑删失的伪值将生存结局转为可按连续结局建模的对象,结合逐一删去观测的计算方法及标准中介分析软件。
材料陈述的贡献
摘要称框架覆盖生存概率、限制平均生存时间及竞争风险累积发生函数,并报告模拟中的无偏性与名义水平错误率控制。
阅读关注点
应核对中介效应的识别条件、删失处理、伪值回归及方差计算,并区分临床案例中的中介证据与替代结局有效性。
阅读边界
这是 arXiv 预印本,同行评审与期刊接收未核实;摘要未说明具体识别和删失条件,模拟结论不能直接推广到所有设计。

原文摘要

Mediation analysis for survival outcomes is challenging. Most existing methods quantify the treatment effect using the hazard ratio (HR) and attempt to decompose the HR into the direct effect of treatment plus an indirect, or mediated, effect. However, the HR is not expressible as an expectation, which complicates this decomposition, both in terms of estimation and interpretation. Here, we present an alternative approach which leverages pseudo-values to simplify estimation and inference. Pseudo-values take censoring into account during their construction, and once derived, can be modeled in the same way as any continuous outcome. Thus, pseudo-values enable mediation analysis for a survival outcome to fit seamlessly into standard mediation software (e.g. CMAverse in R). Pseudo-values are easy to calculate via a leave-one-observation-out procedure (i.e. jackknifing) and the calculation can be accelerated when the influence function of the estimator is known. Mediation analysis for causal effects defined by survival probabilities, restricted mean survival time, and cumulative incidence functions - in the presence of competing risks - can all be performed within this framework. Extensive simulation studies demonstrate that the method is unbiased across 324 scenarios/estimands and controls the type-I error at the nominal level under the null of no mediation. We illustrate the approach using data from the PARADIGMS clinical trial for the treatment of pediatric multiple sclerosis using fingolimod. In particular, we evaluate whether an imaging biomarker lies on the causal path between treatment and time-to-relapse, which aids in justifying this biomarker as a surrogate outcome. Our approach greatly simplifies mediation analysis for survival data and provides a decomposition of the total effect that is both intuitive and interpretable.

笔记与分组